Inoviq Ltd · ASX:IIQ
Inoviq — Investor Presentation (April 2024)
17 slides from Inoviq's investor presentation, Apr 12, 2024
Slide 1: ShareCafe Investor Presentation announcement
12 April 2024 INOVIQ ShareCafe Investor Presentation Melbourne, Australia, 12 April 2024: INOVIQ Limited (ASX:IIQ) (INOVIQ or the Company) advises that CEO Dr Leearne Hinch will provide an investor presentation via ShareCafe - Hidden Gems Webinar on the 12 April 2024. The details and link to registe
Slide 2: ShareCafe Investor Presentation
ShareCafe For personal use only Investor Presentation 12 April 2024 Next-generation diagnostics and therapeutics ASX: IIQ
Slide 3: Important Notice & Disclaimer
Important Notice & Disclaimer For personal use only This presenta tion has been prepa red by INOVIQ Limi ted (“INOVIQ” or the “Company”) Actual resul ts , performance or a chievements could be signi fi cantl y different from those based on i nforma tion a vailable to i tas at the date of this presen
Slide 4: INOVIQ overview
INOVIQ overview | Next generation diagnostics and therapeutics For personal use only $ Financial information (ASX:IIQ) Ordinary shares1 92,018,702 Exosome Disruptive Products Unlisted options 1 8,955,756 powered technology in market 52-week H/L1 A$0.94-0.47 Next-gen exosome Proprietary exosome Exoso
Slide 5: Board & Management
Board & Management For personal use only DAVID WILLIAMS DR GEOFF CUMMING MAX JOHNSTON PHILIP POWELL Non-Executive Chairman Non-Executive Director Non-Executive Director Non-Executive Director Experi enced biotechnology director and Hea lthcare and biotechnology director with Hea lthcare i ndustry di
Slide 6: Business model
Business model | Research tools, diagnostics and therapeutics for cancer For personal use only Core technologies Exosome platform Proprietary exosome isolation technology for research, diagnostics and therapeutics SubB2M technology Novel technology for enhanced cancer diagnosis Business segments Res
Slide 7: Products & pipeline
Products & pipeline | Multi-stage diagnostics and therapeutics pipeline For personal use only TECHNOLOGY RESEARCH TOOLS INDICATION USE RESEARCH VERIFICATION VALIDATION IN-MARKET Exosomes EXO-NET Multiple Pan-EV Capture RUO Exosomes NEURO-NET Neurology Brain Derived-EV Capture RUO Exosomes TEXO-NET O
Slide 8: Exosomes: Significant diagnostic and therapeutic potential
Exosomes | Significant diagnostic and therapeutic potential For personal use only • Exosomes are released by all cells and perform key roles in intercellular communication, immune regulation and disease progression: DNA ➢ Exosomes carry molecular cargo (DNA, RNA, proteins and lipids) that act as RNA
Slide 9: EXO-NET: Exosome isolation products in-market and generating revenue
EXO-NET® | Exosome isolation products in-market and generating revenue For personal use only • Best-in-class EXO-NET pan-exosome capture (research use only) tool in-market EXO-NET and generating revenue PAN-EXOSOME CAPTURE • Enables biomarker discovery and diagnostic development • Offers speed, effi
Slide 10: EXO-NET: Commercial partnerships driving revenue
EXO-NET | Commercial partnerships driving revenue For personal use only Co-Marketing agreement for EXO-NET products worldwide 1 July 2023 Leading provider of innovative technologies, tools and technical support to the global life sciences industry. Based in US and generating revenues of >US$700m. Es
Slide 11: Lead exosome diagnostic: Ovarian Cancer screening test
Lead exosome diagnostic | Ovarian Cancer screening test For personal use only • #8 cancer in women & deadliest gynaecological cancer • 314k new cases of ovarian cancer worldwide pa1 Development Path Ovarian Cancer • 0.25% of population has Hereditary Breast and Ovarian Cancer syndrome2 Feasibility C
Slide 12: Exosome therapeutics: In development for solid tumours
Exosome therapeutics | In development for solid tumours For personal use only Engineered Exosome Isolation & Enrichment • INOVIQ is developing weaponised exosomes engineered to target and treat 150 4×10 9 number of particles total protein (ug) solid tumours 100 3×10 9 • Utilises proprietary EXO-ACE
Slide 13: SubB2M tests for Cancer Monitoring
SubB2M tests for Cancer Monitoring For personal use only INOVIQ is developing solutions for non-invasive, earlier and more accurate tests for cancer monitoring US$6.1b Brea st and Ova rian Cancer di a gnostics market Breast Cancer Ovarian Cancer • #1 cancer in women • #8 cancer in women, deadliest g
Slide 14: SubB2M Breast Cancer clinical data: Outperformed leading CA15-3 test
SubB2M Breast Cancer clinical data | Outperformed leading CA15-3 test For personal use only Clinical Validation Study (2023) 1 | detected all stages SubB2M CA15-3 vs Leading Existing Test Retrospective, case-control, clinical validation study (n=483) Breast Cancer SubB2M Roche ✓ Demonstrated SubB2M
Slide 15: Path-to-Market for SubB2M Breast & Ovarian Cancer monitoring tests
Path-to-Market for SubB2M Breast & Ovarian Cancer monitoring tests For personal use only • SubB2M BC monitoring study successfully Activity CY2024 CY2025 CY2026 completed Feb-24 Assay Development • Engagement with potential US clinical Analytical validation laboratory partners to commercialise as Cl
Slide 16: Summary: Positioned for growth
Summary | Positioned for growth For personal use only Proprietary exosome platform with applications across research, diagnostics and therapeutics Commercial partners secured for EXO-NET to drive revenue growth $ Fee-for-service exosome isolation & biomarker discovery linked to potential diagnostics
Slide 17: Future milestones
Future milestones For personal use only CY 2024 CY 2025 ⚫ Commercial sales of EXO-NET ⚫ Commence development and validation of exosome Agreement with Pharma/Biotech for development of Exosome ⚫ program diagnostic for early detection of Alzheimer’s Disease exosome diagnostic ⚫ Commence analytical and